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anted! The Best Cell
or Cardiac Regeneration*
tefanie Dimmeler, PHD,
ndreas M. Zeiher, MD
rankfurt, Germany
espite the development of novel pharmacological strate-
ies and electrophysiological and surgical treatment regi-
ens, heart failure remains one of the major causes of
ortality in the western world. Heart failure can develop as
consequence of myocardial infarction despite revascular-
zation procedures. Ischemia-induced death of cardiac myo-
ytes results in scar formation and reduced contractility of
he ventricle. Cell therapy for the regeneration of contractile
issue or the improvement of vascularization was proposed
s a novel therapeutic option. Several distinct cell types were
sed in experimental and first clinical pilot trials. The crucial
uestion currently is: which cells are best suited for cardiac
egeneration and vascularization? Obviously, the answer to
his question is complex. Practical and safety issues as well
s the different types of patients we have to treat have a
ajor impact. Moreover, the different routes of cell delivery,
ither by intravenous/intracoronary infusion or intramyo-
ardial injection, can yield different outcomes.
See page 458
At first, cell therapy trials were initiated using skeletal
yoblasts, which were isolated from muscle biopsies. Skel-
tal myoblasts were injected into the myocardium during
pen-heart surgery or by injection catheter. Although skel-
tal muscle cells improved heart function in animal models
nd in a pilot trial (1), the enthusiasm was dampened by the
ccurrence of life-threatening arrhythmias, which were
ost likely caused by the lack of connexin expression and
he failure of skeletal muscle cells to couple to neighboring
ardiac myocytes (2).
Stem cells are a second option to be used for cardiac
egeneration. Although embryonic stem cells are by nature
ore versatile than their adult counterparts, increasing
vidence suggests that stem and progenitor cells of the adult
rganisms also have a capacity to give rise to several lineages
nd may be suitable for regenerative medicine (3). The
est-established source is the bone marrow. Bone marrow
ontains the hematopoietic stem cells, which have been used
or stem cell transplantation for more than 25 years in
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From Molecular Cardiology, Department of Internal Medicine IV, University of
rankfurt, Theodor-Stern-Kai 7, Frankfurt, Germany. The authors are funded
sntirely by the Deutsche Forschungsgemeinschaft (DFG).ematology. These cells are characterized by the human
arker proteins CD34 or the more immature marker
rotein CD133. Mesenchymal stem cells also can be iso-
ated from bone marrow. The group of Verfaillie succeeded
n isolating multipotent adult progenitor cells, which differ-
ntiate, at the single cell level, not only into mesenchymal
ells but also into cells with visceral mesoderm, neuroecto-
erm, and endoderm characteristics in vitro (4). Bone
arrow-derived cells (hematopoietic stem cells, endothelial
rogenitor cells, mesenchymal stem cells, or side-population
ells) were shown to express endothelial and/or cardiomyo-
enic markers (5) and to profoundly increase functional
ecovery after myocardial infarction (6–8).
In this issue of the Journal, Agbulut et al. (9) report on a
ide-by-side comparison of two different cell types: purified
D133 hematopoietic progenitor cells and skeletal myo-
lasts. Both cell types were injected into the infarcted
yocardium 10 days after ligation of the left coronary artery
f immunodeficient rats and elicited similar improvement in
lobal left ventricular function as assessed by echocardiog-
aphy and left ventricular pressure-volume loops one month
fter transplantation. Despite the significant functional
mprovement induced by both cell types, the authors failed
o detect engrafted CD133 hematopoietic progenitor
ells by immunohistochemistry, whereas skeletal myoblasts
howed robust engraftment. These findings appear to be
onsistent with recent reports questioning the capacity of
urified hematopoietic progenitor cells to differentiate into
ardiac myocytes when directly injected into the infarcted
yocardium after permanent coronary occlusion (10,11),
hereas unselected expanded bone marrow cells robustly
ngrafted in a rabbit model of myocardial cyroinjury (12).
he question, however, remains how the injected CD133
ells mediate improved left ventricular function despite the
bvious lack of robust engraftment into the infarcted area.
urprisingly, Agubulut et al. (9) did not observe any
ifferences in capillary density in the border zone of the
nfarcts in culture medium-injected control animals com-
ared with either CD133 cells or skeletal myoblast-
njected animals, suggesting that enhanced angiogenesis
oes not contribute to improved left ventricular function
fter the injection of CD133 cells or skeletal myoblasts.
hese findings contrast with previous reports documenting
significant increase in capillary density after intravenous
nfusion of CD34 bone marrow-derived hematopoietic
ells (13) or both intravenous infusion or injection of
lood-derived progenitor cells (7,14) immediately after
xperimentally induced myocardial infarction. This discrep-
ncy might be explained by the different cell types studied or
y the timing of cell transplantation after induction of
yocardial infarction: whereas the researchers in those
tudies documenting increased capillary density after the
ransplantation of progenitor cells applied cell therapy
mmediately after the induction of ischemia, in the present
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eems likely that 10 days after permanent occlusion of a
oronary artery, the microenvironment in the infarcted and
n the border zone does not favor cell transplantation-
nduced neovascularization.
The failure to detect increased neovascularization in the
resent study leaves two potential mechanisms to explain
he beneficial effects of cell transplantation on left ventric-
lar function: interference with scar formation by altering
xtracellular matrix formation within the healing myocardial
nfarction and/or the recruitment of cardiac resident stem
ells by the release of progenitor cell-derived mediators.
owever, none of these mechanisms has yet been formally
ested to occur after progenitor cell transplantation. The
escue of reversibly damaged host cardiomyocytes appears to
e rather unlikely given that cardiac myocyte death is
ompleted 10 days after permanent coronary artery occlu-
ion. In support of a cytokine-mediated paracrine effect are
revious studies showing that skeletal myoblasts, although
obustly engrafted into infarcted myocardium, remain func-
ionally isolated (2), do not electrically couple, and remain
ineage-restricted, e.g., do not express cardiomyocyte-
pecific markers (9). Further studies will have to address
hether, for cytokine-mediated paracrine effects to become
perative, it is essential that transplanted cells robustly
ngraft or whether a transient retention of transplanted cells
ithin the infarcted area is sufficient to mediate functional
mprovement, as suggested by the present study, where
ngrafted CD133 cells could not be detected one month
fter injection.
LINICAL IMPLICATIONS
ow do the reported observations translate into clinical
ractice? First of all, the present study attempted to mimic
subchronic state of myocardial infarction. As such, it does
ot readily apply to clinical attempts to use progenitor cell
ransplantation in patients with acute myocardial infarction.
he two published studies reporting a beneficial effect of
ransplantation of bone marrow-derived or blood-derived
rogenitor cells used an intracoronary route of application of
rogenitor cells in patients with reperfused acute myocardial
nfarction (15,16). Importantly, ischemic but non-necrotic
ardiac tissue up-regulates a variety of cardioprotective but
lso progenitor cell-attracting and survival-promoting che-
okines and transcription factors such as vascular endo-
helial growth factor, stromal cell-derived factor-1, and
ypoxia-inducible factor-1 (17). Thus, the local environ-
ent within the reperfused infarcts with islands of viable
yocardium and release of cellular survival factors may
reatly favor recruitment but also survival and potentially
ngraftment of progenitor cells transplanted via an intra-
rterial route into the infarct area. In contrast, it is difficult
o envisage that progenitor cells that are directly injected
nto necrotic tissue with a completely destructed syncytium
nd deprived of blood flow-delivering oxygen and nutrients uill receive any cues or signals to differentiate into cardiac
yocytes or vascular cells. As such, it is also not surprising
hat recent studies in mice with permanent occlusion-
nduced myocardial infarction and direct intranecrosis-
njected CD34 hematopoietic progenitor cells did not
bserve any substantial numbers of engrafted or differenti-
ted cells bearing markers of cardiac myocytes (11), but the
njected cells rather adopted mature hematopoietic fates
10).
The present study, however, is more applicable to clinical
ttempts to improve heart function in semichronic myocar-
ial infarction. Although scar formation is clearly not
ompleted after 10 days of a non-reperfused myocardial
nfarction (18), skeletal myoblasts transplanted by intramyo-
ardial injection appear to have a survival and engraftment
dvantage compared with CD133 progenitor cells during
he healing phase of myocardial infarction. Nevertheless,
he observed functional improvement supports recent pre-
iminary clinical data showing improved regional perfusion
nd contractile function after intramyocardial injection of
D133 progenitor cells during bypass surgery in patients
ith 4- to 12-week-old myocardial infarction (19). How-
ver, it should be kept in mind that these patients simulta-
eously underwent bypass surgery that provided an oxygen
upply and nutrient blood flow to the infarcted myocardial
rea that was transplanted with progenitor cells. Finally, the
wo other studies reporting beneficial effects on regional left
entricular function after intramyocardial injection of bone
arrow-derived mononuclear cells selected patients with
vidence of hibernating myocardium by the electromechan-
cal mapping technique (20,21). Thus, despite the presence
f chronic myocardial ischemia and infarction, the regions
njected with progenitor cells contained viable myocardium
nd, thus, may have provided a more favorable microenvi-
onment for injected cells compared with the non-
eperfused 10-day-old infarctions treated in the present
tudy.
In summary, although the authors should be congratu-
ated for a thorough experimental head-to-head comparison
f different cell types currently under clinical investigation
or enhancing cardiac repair after myocardial infarction,
areful interpretation of the results should be used when
ranslating these experimental findings into clinical practice.
ncouragingly, both skeletal myoblasts as well as CD133
ematopoietic progenitor cells appear to be associated with
he improvement of left ventricular function after experi-
entally induced myocardial infarction. Nevertheless, the
uest for the best (adult) cell for cardiac regeneration is still
ngoing, if there is any regeneration in its pure sense at all
r only modifications in the infarct healing process. As it is
ith many pioneering studies, careful examinations not only
ill provide conclusive answers but may leave even more
pen questions. Finally, it should not be dismissed that
linical practicability and, most importantly, safety will
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